Skip to main content
Paul Johannet, MD, Oncology, New York, NY

Paul Medalia Johannet MD

Gynecologic Cancer


Physician

Request Appointment
  • 160 East 53rd StreetNew York, NY 10022

  • Book by Phone+1(765) 719-7803

Overview of  Dr. Johannet

Dr. Paul Johannet is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Veterans Affairs New York Harbor Healthcare System. He received his medical degree from Stanford University School of Medicine and has been in practice 9 years. He is one of 37 doctors at Veterans Affairs New York Harbor Healthcare System and one of 527 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 30 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2021
  • Sidney Kimmel Medical College at Thomas Jefferson University/TJUH
    Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Gastroenterology, 2019 - 2025
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 2018 - 2021
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 2017

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2024 - Present
  • NJ State Medical License
    NJ State Medical License 2024 - 2027
  • NY State Medical License
    NY State Medical License 2020 - 2027
  • PA State Medical License
    PA State Medical License 2024 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Lectures

  • Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Promising Clinical Trial Predicts Cancer Risk and Recurrence in Patients Treated with Immunotherapy
    Promising Clinical Trial Predicts Cancer Risk and Recurrence in Patients Treated with ImmunotherapySeptember 15th, 2022

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: